Medical Policy

BlueCross BlueShield Kansas
An Independent licensee of the Blue Cross Blue Shield Association

Title: Cryoablation of Tumors Located in the Kidney, Lung, Breast, Pancreas, or Bone

Related Policies:	▪ *Cryosurgical Ablation of Primary or Metastatic Liver Tumors* ▪ *Radiofrequency Ablation of Primary or Metastatic Liver Tumors* ▪ *Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors*

Professional / Institutional
Original Effective Date: March 4, 2019
Latest Review Date: September 8, 2026
Current Effective Date: September 8, 2026

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact Blue Cross and Blue Shield of Kansas Customer Service.

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

Populations	Interventions	Comparators	Outcomes
Individuals: • With early stage renal cancer who are surgical candidates	Interventions of interest are: • Cryoablation	Comparators of interest are: • Surgical resection • Active surveillance	Relevant outcomes include: • Overall survival • Disease-specific survival • Quality of life • Treatment-related morbidity
Individuals: • With early stage renal cancer who	Interventions of interest are: • Cryoablation	Comparators of interest are: • Active surveillance	Relevant outcomes include: • Overall survival • Disease-specific survival

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Populations	Interventions	Comparators	Outcomes
are not surgical candidates			• Quality of life • Treatment-related morbidity
Individuals: • With non-small cell lung cancer who are not surgical candidates	Interventions of interest are: • Cryoablation	Comparators of interest are: • Radiation therapy • Palliative care	Relevant outcomes include: • Overall survival • Disease-specific survival • Quality of life • Treatment-related morbidity
Individuals: • With non-small cell lung cancer who require palliation for a central airway obstructing lesion	Interventions of interest are: • Cryoablation	Comparators of interest are: • Surgical resection • Radiation therapy • Palliative care	Relevant outcomes include: • Overall survival • Disease-specific survival • Quality of life • Treatment-related morbidity
Individuals: • With low-risk, early-stage breast cancer	Interventions of interest are: • Cryoablation	Comparators of interest are: • Surgical resection • Radiation therapy • Palliative care	Relevant outcomes include: • Overall survival • Disease-specific survival • Quality of life • Treatment-related morbidity
Individuals: • With solid tumors located in the pancreas, kidney, or bone	Interventions of interest are: • Cryoablation	Comparators of interest are: • Surgical resection • Other ablative techniques • No intervention	Relevant outcomes include: • Overall survival • Disease-specific survival • Quality of life • Treatment-related morbidity

DESCRIPTION

Cryosurgical ablation (hereafter referred to as cryosurgery or cryoablation) involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

OBJECTIVE

The objective of this evidence review is to determine whether cryoablation of tumors located in the kidney, lung, breast, pancreas, or bone will improve the net health outcome. This evidence review is limited to treatment in adults (age 18 years and older) and does not address pediatric populations.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

BACKGROUND

Renal Tumors
Localized kidney cancer is treated with radical nephrectomy or nephron-sparing surgery. Prognosis drops precipitously if the tumor extends outside the kidney capsule because chemotherapy is relatively ineffective against metastatic renal cell carcinoma.

Lung Tumors and Lung Metastases
Early-stage lung tumors are typically treated surgically. Patients with early-stage lung cancer who are not surgical candidates may be candidates for radiotherapy with curative intent. Cryoablation is being investigated in patients who are medically inoperable, with small primary lung cancers or lung metastases from extrapulmonary primaries. Patients with a more advanced local disease or metastatic disease may undergo chemotherapy with radiation following resection. Treatment is rarely curative; rather, it seeks to retard tumor growth or palliate symptoms.

Breast Tumors
Early-stage primary breast cancers are treated surgically. The selection of lumpectomy, modified radical mastectomy, or another approach is balanced against the patient's desire for breast conservation, the need for tumor-free margins in resected tissue, and the patient's age, hormone receptor status, and other factors. Adjuvant radiotherapy decreases local recurrences, particularly for those who select lumpectomy. Adjuvant hormonal therapy and/or chemotherapy are added, depending on the presence and number of involved nodes, hormone receptor status, and other factors. Treatment of metastatic disease includes surgery to remove the lesion and combination chemotherapy.

Fibroadenomas are common benign tumors of the breast that can present as a palpable mass or a mammographic abnormality. These benign tumors are frequently surgically excised to rule out a malignancy.

Pancreatic Cancer
Pancreatic cancer is a relatively rare solid tumor that occurs almost exclusively in adults, and it is largely considered incurable. Surgical resection of tumors contained entirely within the pancreas is currently the only potentially curative treatment. However, the nature of the cancer is such that few tumors are found at such an early and potentially curable stage. Patients with a more advanced local disease or metastatic disease may undergo chemotherapy with radiation following resection. Treatment focuses on slowing tumor growth and palliation of symptoms.

Bone Cancer and Bone Metastases
Primary bone cancers are extremely rare, accounting for less than 0.2% of all cancers. Bone metastases are more common, with clinical complications including debilitating bone pain. Treatment for bone metastases is performed to relieve local bone pain, provide stabilization, and prevent impending fracture or spinal cord compression.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

REGULATORY STATUS

Several cryoablation devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for use in open, minimally invasive, or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, proctology, thoracic surgery, and ear, nose, and throat. Examples include:

- Cryocare® Surgical System (Endocare);
- CryoGen Cryosurgical System (Cryosurgical);
- CryoHit® (Galil Medical) for the treatment of breast fibroadenoma;
- IceSense3™, ProSense™, and MultiSense Systems (IceCure Medical);
- SeedNet™ System (Galil Medical); and
- Visica® System (Sanarus Medical).

FDA product code: GEH.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

POLICY

A. Cryosurgical ablation may be considered **medically necessary** to treat localized renal cell carcinoma that is no more than 4 cm in size when either of the following criteria is met:

   1. Preservation of kidney function is necessary (i.e., the individual has 1 kidney or renal insufficiency defined by a glomerular filtration rate of <60 mL/min/m2), and standard surgical approach (i.e., resection of renal tissue) is likely to worsen kidney function substantially; **OR**
   2. The individual is not considered a surgical candidate.

B. Cryosurgical ablation may be considered **medically necessary** to treat lung cancer when either of the following criteria is met:

   1. The individual has early-stage non-small-cell lung cancer and is a poor surgical candidate; **OR**
   2. The individual requires palliation for a central airway obstructing lesion.

C. Cryosurgical ablation is considered **experimental / investigational** as a treatment for benign or malignant tumors of the breast.

D. Cryosurgical ablation is considered **experimental / investigational** as a treatment for lung (other than defined above), pancreas, or bone, and to treat renal cell carcinomas in individuals who are surgical candidates.

Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

RATIONALE

This evidence review was created using with searches of the PubMed database. The most recent literature update was performed through May 18, 2026.

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

CRYOABLATION FOR EARLY STAGE KIDNEY CANCER

Clinical Context and Therapy Purpose

The purpose of cryoablation in individuals who have early stage kidney cancer is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with early stage kidney tumors.
The review of evidence addresses the use of cryoablation in 2 populations who have early stage renal cancer:

1. Individuals who are candidates for surgery;
2. Individuals who are not surgical candidates. Individuals with 1 kidney or with renal insufficiency are likely to be deemed poor surgical candidates because a standard surgical approach (i.e., resection of renal tissue) is likely to worsen kidney function substantially.

Interventions

The therapy being considered is cryoablation, also referred to as cryosurgery.

Cryoablation involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

Comparators

For individuals with stage 1 kidney cancer who are surgical candidates, the comparator of interest is surgical resection. Surgery by partial nephrectomy, whenever feasible, or by radical nephrectomy is the standard of care for stage 1 kidney cancer.

For select individuals, including those with small renal masses <2 cm or significant competing risks of death or morbidity from intervention, active surveillance is an option. Active surveillance entails serial abdominal imaging and periodic metastatic survey, including blood work and chest imaging.

Outcomes

The general outcomes of interest are overall survival (OS), disease-specific survival, quality of life, and treatment-related morbidity.

The hypothesized advantages of cryosurgery include improved local control and benefits common to any minimally invasive procedure (eg, preserving normal organ tissue, decreasing morbidity, decreasing length of hospitalization). For individuals who are not surgical candidates due to renal insufficiency or who have 1 kidney, preservation of renal function is important.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Potential complications of cryosurgery include those caused by hypothermic damage to normal tissue adjacent to the tumor, structural damage along the probe track, and secondary tumors if cancerous cells are seeded during probe removal.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess long-term outcomes and adverse events, single-arm studies that captured longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

REVIEW OF EVIDENCE

INDIVIDUALS WITH EARLY STAGE KIDNEY CANCER WHO ARE SURGICAL CANDIDATES

Randomized Controlled Trials

There are no randomized controlled trials of cryoablation compared to surgery for kidney cancer that were identified.

Systematic Reviews

Multiple systematic reviews of comparative observational studies have compared cryoablation to partial nephrectomy in patients with early kidney cancer. This section summarizes the most recent, relevant, and comprehensive reviews and meta-analyses, reported by Gao et al (2024),[1,] Yanagisawa et al (2022),[2,] Uhlig et al (2019),[3,] Klatte et al (2014),[4,] and Tang et al (2014).[5,] Included studies and characteristics of the systematic reviews are described in Tables 1 and 2. The Yanagisawa et al (2022) review includes multiple types of ablation therapies (radiofrequency ablation [RFA], cryoablation, and microwave ablation) - only studies that focus on cryoablation are listed in Table 1.

Table 1. Cryoablation Studies Included in Systematic Reviews and Meta-Analyses Comparing Cryoablation to Partial Nephrectomy

Study	Gao et al (2024)[1,]	Yanagisawa et al (2022)[2,]	Uhlig et al (2018)[3,])	Klatte et al (2014)[4,]	Tang et al (2014)[5,]
Andrews et al (2019)		●			
Atwell et al (2013)			●		
Bhindi et al (2017)			●		
Bertolo et al (2019)	●				
Camacho et al (2016)			●		
Caputo et al (2017)	●	●	●		

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Study	Gao et al (2024)[1,]	Yanagisawa et al (2022)[2,]	Uhlig et al (2018)[3,])	Klatte et al (2014)[4,]	Tang et al (2014)[5,]
Chehab et al (2016)			●		
Danzig et al (2015)			●		
Desai et al (2005)		●	●	●	●
Emara et al (2014)	●		●	●	●
Fosatti et al (2015)		●			
Foyil et al (2008)			●		
Fraisse et al (2019)	●				
Garcia et al (2021)		●			
Guillotreau et al (2012)	●	●	●	●	●
Haber et al (2012)			●	●	●
Haramis et al (2012)		●	●	●	●
Hegarty et al (2006)			●		
Hinshaw et al 2016)			●		
Hruby et al (2006)				●	●
Kawaguchi et al (2022)	●				
Kim et al (2007)				●	
Kiriluk et al (2011)					●
Klatte et al (2011)		●	●		
Ko et al (2008)		●			
Lian et al (2010)				●	
Lin et al (2008)				●	●
Liu et al (2021)	●	●			
Lughezzani et al (2009)			●	●	
Mason et al (2017)			●		
Nisbett et al (2009)				●	
O'Malley et al (2007)			●	●	●
Panumatrassamee et al (2013)			●		
Rembeyo et al (2020)	●	●			
Tanagho et al (2013)	●		●		

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Study	Gao et al (2024)[1,]	Yanagisawa et al (2022)[2,]	Uhlig et al (2018)[3,])	Klatte et al (2014)[4,]	Tang et al (2014)[5,]
Thompson et al (2015)			●		
Turna et al (2009)			●	●	
Uemura et al (2021)	●				
Weinberg et al (2015)			●		
Yanagisawa et al (2018)		●			
Zechlinski et al (2016)			●		

Table 2. Systematic Reviews and Meta-Analyses Comparing Cryoablation to Partial Nephrectomy- Study Characteristics

Study	Search End Date	Study Inclusion Criteria	Studies Included	Mean Tumor size	Sample size	Follow-up Duration (months)
Gao et al (2024)[1,]	November 2023	Compared robot-assisted PN to cryoablation in the treatment of cT1 renal tumors. Reported on clinical outcomes, which included complication rate, hospitalization period, % decline in eGFR, recurrence, and mortality from disease. Retrospective and prospective studies were included.	Total = 10 (2011 patients) All retrospective	Cryoablation: 2.64 cm PN: 2.75 cm	Cryoablation: 1029 PN: 982	Range 4.5 to 55
Yanagisawa et al (2022)[2,]	August 2021	Compared AT (RFA, MWA, or cryoablation) with PN in the treatment of cT1a and cT1b	Total = 27 (13,996 patients) 12 studies focused on cryoablation	18 studies comprise cT1a patients, 6 studies comprise	cT1a: 13,062 cT1b: 934	Not described

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Study	Search End Date	Study Inclusion Criteria	Studies Included	Mean Tumor size	Sample size	Follow-up Duration (months)
		renal tumors. Reported on clinical outcomes, which included complication rate, hospitalization period, % decline in eGFR, recurrence, secondary efficacy, metastasis, and mortality from disease. Retrospective and prospective studies were included.	compared with PN	cT1b patients, and 3 studies include both.		
Uhlig et al (2018)[3,]	December 2017	Evaluated PN, RFA, cryoablation, or MWA for treatment of renal masses; Comparative study design contrasting at least 2 different interventions; Assessed at least 1 of the following end points: all-cause mortality, cancer-specific mortality, local recurrence, complications or change in renal function. Retrospective and	Total = 47 (24,077 patients) 13 prospective, 34 retrospective Cryoablation: 24 studies (668 patients)	Cryoablation: 2.53 cm PN: 2.84 cm MWA: 2.74 cm RFA: 2.63 cm	Cryoablation: 6,618 PN: 15,238 MWA: 344 RFA: 1,877	Range 3 to 82

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Study	Search End Date	Study Inclusion Criteria	Studies Included	Mean Tumor size	Sample size	Follow-up Duration (months)
		prospective studies were included.				
Klatte et al (2014)[4,]	September 2013	Compared laparoscopic cryoablation with laparoscopic PN or robot-assisted laparoscopic PN for the treatment of small renal tumors; Reported perioperative outcomes or data on histology and oncologic outcomes were provided.	Total = 13 (1191 patients) All retrospective	Cryoablation: 2.28 cm PN: 2.41 cm	Cryoablation: 627 PN: 564	Mean Cryoablation: 22.5 PN: 29.5
Tang et al (2014)[5,]	September 2013	Compared laparoscopic cryoablation and laparoscopic PN for small renal masses; Reported on at least 1 of the following outcomes: operating time, estimated blood loss, length of hospital stay, blood transfusion rate, conversions rate, postoperative serum creatinine increase,	Total = 92 prospective, 7 retrospective	Not reported	Cryoablation: 555 PN: 642	Range Cryoablation: 11.9 to 44.5 PN: 4.8 to 42.7

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Study	Search End Date	Study Inclusion Criteria	Studies Included	Mean Tumor size	Sample size	Follow-up Duration (months)
		postoperative glomerular filtration rate decrease, catheterization time, local recurrence, distant metastasis, and overall complications, including both intraoperative and postoperative minor and major complications; Clearly documented indications for resection of the renal tumor.				

AT: ablation therapy; eGFR: estimated glomerular filtration rate; MWA: microwave ablation; PN: partial nephrectomy; RFA: radiofrequency ablation

Gao et al (2024) published a systematic review and meta-analysis comparing robot-assisted partial nephrectomy to cryoablation.[1,] Ten retrospective trials published between 2012 and 2022 (N=2011) were included. There were no significant differences in terms of recurrence-free survival or OS between the partial nephrectomy and cryoablation groups. Additionally, there were no differences in changes in kidney function at 1 year post-surgery. The overall incidence of complications was significantly lower in the cryoablation group compared to partial nephrectomy; however, cryoablation showed significantly higher tumor recurrence rates compared to partial nephrectomy (see Table 3).

Yanagisawa et al (2022) published a systematic review and meta-analysis comparing ablative therapies (cryoablation, RFA, and microwave ablation) to partial nephrectomy.[2,] Twenty-seven trials published between 2005 and 2021 (N=13,996) were included; 12 of those studies directly compared cryoablation with partial nephrectomy, although results were not stratified by type of ablative therapy (see Table 3). No significant differences in cancer-specific mortality for cT1a tumors (p=.50) and cT1b tumors (p=.63) were found comparing partial nephrectomy and ablation therapies. Local recurrence was higher for ablative therapies compared with partial nephrectomy in both cT1a tumors (risk ratio, 0.43; 95% confidence interval [CI], 0.28 to 03.66; p=.0001) and cT1b tumors (risk ratio, 0.41; 95% CI, 0.23 to 0.75; p=.004). There were no significant differences between partial nephrectomy and ablation therapy in terms of rate of metastases, overall complications, and decline in renal function.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Uhlig et al (2019) published a systematic review and meta-analysis comparing partial nephrectomy, RFA, cryoablation, and microwave ablation for small renal masses.[3,] Forty-seven studies published between 2005 and 2017, with a total of 24077 participants, were included. Of these, 24 studies were conducted in 668 patients, comparing cryoablation to partial or another ablative technique. Table 3 summarizes the results of the network meta-analysis for the comparison of cryoablation to partial nephrectomy. No significant difference in cancer-specific mortality for partial nephrectomy (p=.8065), cryoablation (p=.5519), RFA (p=.3496), and microwave ablation (p=.2920) was found. Local recurrence was higher for cryoablation, RFA, and microwave ablation compared with partial nephrectomy (respectively, incidence rate ratio=4.13; incidence rate ratio=1.79; incidence rate ratio, 2.52; p<.05). There was a less pronounced decline in renal function for RFA compared with partial nephrectomy, cryoablation, and microwave (respectively, mean difference in glomerular filtration rate 6.49; 5.82; 10.89; p<.05).

Tang et al (2014) reported on a systematic review and meta-analysis comparing renal laparoscopic renal cryoablation with laparoscopic partial nephrectomy in the treatment of small renal masses.[5,] Reviewers identified 9 trials (2 prospective, 7 retrospective) in which the 2 techniques were assessed (555 cases, 642 controls). Laparoscopic cryoablation was associated with statistically significant shorter surgical times, less blood loss, and fewer overall complications; however, it was estimated that laparoscopic partial nephrectomy might have a significantly lower local recurrence rate (odds ratio [OR], 13.03; 95% CI, 4.20 to 40.39; p<.001) and lower distant metastasis rate (OR, 9.05; 95% CI, 2.31 to 35.51; p=.002).

Klatte et al (2014) also reported on a systematic review and meta-analysis comparing laparoscopic renal cryoablation with laparoscopic partial nephrectomy for small renal tumors.[4,] Thirteen nonrandomized studies were selected for analysis, which found cryoablation was associated with better perioperative outcomes than laparoscopic partial nephrectomy. Oncologic outcomes, however, were inferior with cryoablation, which was significantly associated with a greater risk of local (relative risk, 9.39) and metastatic (relative risk, 4.68) tumor progression.

Table 3. Systematic Reviews and Meta-Analyses Comparing Cryoablation to Partial Nephrectomy- Study Results

Study	All-Cause Mortality	Cancer-Specific Mortality	Local Recurrence	Metastases	Complications	Decline in Renal Function
Gao et al (2024)[1,]						
Cryoablation vs PN: OR/MD/HR (95% CI); p-value	OS: HR, 0.95 (0.34 to 2.68);.92	RFS: HR, 1.06 (0.47 to 2.39);.88	OR, 7.83 (4.32 to 14.19); <.00001	Not assessed	OR, 0.62 (0.45 to 0.86);.004	MD at 12 months post-surgery, 1.10 (-4.33 to 6.54);.69
I^2 (P-value)	0% (.94)	0% (.76)	21% (.26)		56% (.02)	79% (.009)
Yanagisawa et al (2022)[2,]						

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Study	All-Cause Mortality	Cancer-Specific Mortality	Local Recurrence	Metastases	Complications	Decline in Renal Function
cT1a tumors: Risk ratio (95% CI); p-value	Not assessed	0.87 (0.57 to 1.31);.50	0.43 (0.28 to 0.66);.0001 Favors PN	0.79 (0.47 to 1.34);.39	1.34 (0.90 to 2.0);.15	MD, 2.42 (-0.06 to 4.89);.06
I^2 (P-value)		0% (.62)	20% (.23)	20% (.28)	63% (.0003)	83% (.0004)
cT1b tumors: Risk ratio (95% CI); p-value	Not assessed	0.80 (0.32 to 1.98);.63	0.41 (0.23 to 0.75);.004 Favors PN	1.16 (0.51 to 2.64);.72	1.08 (0.76 to 1.53);.68	MD, 0.73 (-3.76 to 5.23);.75
I^2 (P-value)		0% (.76)	30% (.20)	28% (.23)	22% (.26)	0% (.71)
Uhlig et al (2019)[3,]						
Network meta-analysis Cryoablation vs PN IRR (95% CI) P-value	2.58 (1.92 to 3.46)<.001	2.27 (0.79 to 6.49) .126	4.13 (2.28 to 7.47).001	Not assessed	0.67 (0.48 to 0.92).013	0.66 (-3.18 to 4.51).736
I^2 (P-value)	0% (.968)	0% (.8283)	29.4% (.6784)		59.9% (.003)	91.8% (.9001)
Klatte et al (2014)[4,]						
Relative Risk (95% CI); P-value	Not assessed	Not assessed	Local Progression: 9.39 (3.83 to 22.98); <.0001	Metastatic Progression: 4.68 (1.88 to 11.64); <.001	Complications Total: 1.82 (1.22 to 2.72) Urological: 1.99 (1.10 to 3.63) Non-urological: 2.33 (1.42 to 3.84) Favors cryoablation	Not assessed
Tang et al (2014)[5,]						
OR /Weighted MD (95% CI); P-value	Not assessed	Not assessed	13.03 (4.20 to 40.39); <.001	9.05 (2.31 to 35.51);.002	Overall: 0.53 (0.29 to 0.98);.04 Major: 0.45 (0.25 to 0.81);.008	SCr % increase: -6.77 (-13.79 to 0.24);.06 GFR decrease: -1.83 (-7.61 to 3.96);.44

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Study	All-Cause Mortality	Cancer-Specific Mortality	Local Recurrence	Metastases	Complications	Decline in Renal Function
					Minor: 0.65 (0.33 to 1.28);.21 Postoperative: 0.61 (0.32 to 1.15);.13 Intraoperative: 0.20 (0.07 to 0.58);.003	
I^2 (P-value)			5% (.38)	0% (.79)	Overall: 61% (.009) Major: 0% (.48) Minor: 53% (.03) Postoperative: 60% (.01) Intraoperative: 0% (.89)	SCr % increase: 61% (.08) GFR decrease: 79% (.002)

CI: confidence interval; GFR: glomerular filtration rate; HR: hazard ratio; IRR: incidence rate ratio; MD: mean difference; OR: odds ratio; OS: overall survival; PN: partial nephrectomy; RFS: recurrence-free survival; SCr: serum creatinine

Comparative Observational Studies

This section summarizes recent comparative studies of cryoablation and partial nephrectomy not included in any of the systematic reviews discussed above.

Andrews et al (2019) reported on 1798 patients with primary stage 1 renal masses treated with partial nephrectomy, percutaneous RFA, or percutaneous cryoablation between 2000 and 2011 at Mayo Clinic.[6,] A total of 1422 patients were treated with partial nephrectomy (n=1055), RFA (n=180), or cryoablation (n=187) for stage 1a renal masses, and 376 patients were treated with partial nephrectomy (n=324) or cryoablation (n=52) for stage 1b renal masses. Comparisons of cryoablation to partial nephrectomy among 1422 patients with stage 1a masses resulted in hazard ratios (HRs) of 1.88 (95% CI, 0.76 to 4.66; p=.18), 0.23 (95% CI, 0.03 to 1.72; p=.15), and 0.29 (95% CI, 0.01 to 6.11; p=.40) for local recurrence, metastases, and death from renal cell carcinoma, respectively. Five-year cancer-specific survival was 99%, 96%, and 100% for partial nephrectomy, RFA, and cryoablation, respectively. Among 376 stage 1b patients, 324 and 52 underwent partial nephrectomy and cryoablation with median clinical follow-up of 8.7 and 6.0 years, respectively. Comparisons of cryoablation with partial nephrectomy resulted in HRs of 1.22 (95% CI, 0.33 to 4.48; p=.80), 0.95 (95% CI, 0.21 to 4.38; p>.90), and 1.94 (95% CI, 0.42 to 8.96; p=.40) for local recurrence, metastases, and death from renal cell carcinoma, respectively. Five-year cancer-specific survival was 98% and 91% for partial nephrectomy and cryoablation, respectively.

A retrospective, nonrandomized analysis of prospectively collected data compared robot-assisted partial nephrectomy with percutaneous ablation in patients with T1b renal cell carcinoma.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Rembeyo et al (2020) compared patients treated with robot-assisted partial nephrectomy (n=36), cryoablation (n=55), and RFA (n=11).[7,] Median tumor sizes in each group were 4.5, 4.6, and 4.2 cm, respectively, and median follow-up times were 23.7, 19.9, and 51.3 months. Compared with partial nephrectomy, local recurrence-free survival was significantly shorter with cryoablation (adjusted HR, 4.3; 95% CI, 1.78 to 10.37). Two-year local recurrence-free survival rates for the partial nephrectomy, cryoablation, and RFA groups were 89.1%, 73.5%, and 81.8%, respectively (p<.001).

A retrospective, nonrandomized study also compared partial nephrectomy with cryoablation and RFA, specifically in patients with T1aN0M0 renal cell carcinoma with tumor size ≤4 cm. Yan et al (2019), using Medicare Surveillance, Epidemiology, and End Results (SEER) data, compared OS and cancer-specific survival in patients treated with partial nephrectomy (n=15,395), cryoablation (n=1,381), and RFA (n=457).[8,] Median follow-up was 30 months in all groups. Overall survival was significantly improved with partial nephrectomy compared with cryoablation (HR, 2.995; 95% CI, 2.363 to 3.794) and RFA (HR, 4.085; 95% CI, 2.683 to 6.220). Similarly, cancer-specific survival was significantly improved with partial nephrectomy compared with cryoablation (HR, 3.562, 95% CI, 1.399 to 6.220) and RFA (HR, 3.457; 95% CI, 2.043 to 5.850). In subgroup analyses of patients with tumor size ≤2 cm, OS was again significantly improved with partial nephrectomy versus cryoablation (HR, 1.958; 95% CI, 1.204 to 3.184) and RFA (HR, 2.841; 95% CI, 1.211 to 6.662); however, cancer-specific survival was not different. In patients with tumor size 2 to 4 cm, OS was significantly improved with partial nephrectomy versus cryoablation (HR, 3.284; 95% CI, 2.513 to 4.292) and versus RFA (HR, 4.497; 95% CI, 2.782 to 7.269), as was cancer-specific survival (partial nephrectomy vs. cryoablation: HR, 3.536; 95% CI, 2.006 to 6.234; partial nephrectomy vs RFA: HR, 4.339; 95% CI, 1.573 to 11.971).

Another analysis of Medicare SEER data retrospectively compared partial nephrectomy with cryoablation in patients with T1b nonmetastatic renal cell carcinoma. Pecoraro et al (2019) compared patients undergoing cryoablation (n=434) with propensity score-matched patients undergoing partial nephrectomy (n=228).[9,] In patients treated with cryoablation versus partial nephrectomy at 5 years, cancer-specific mortality rates were 7.6% versus 2.8%, respectively (p=.02), and other-cause mortality rates were 17.9% versus 11.8% (p=.1). Findings were consistent in multivariable analyses, where other-cause mortality remained nonsignificant, and cryoablation was associated with a higher risk of mortality (adjusted HR, 2.50).

Section Summary: Individuals with Early Stage Kidney Cancer who Are Surgical Candidates

Multiple comparative observational studies and systematic reviews of these studies have compared cryoablation to partial nephrectomy for early-stage renal cancer. These studies have consistently found that partial nephrectomy is associated with better oncological outcomes than cryosurgery.

Individuals with Early Stage Kidney Cancer who Are Not Surgical Candidates

There are no RCTs or comparative observational studies comparing cryoablation to active surveillance in patients with kidney cancer who are not surgical candidates were identified.

Systematic Reviews

Although there are no systematic reviews directly comparing cryoablation with active surveillance in patients who are not surgical candidates, multiple systematic reviews of cryoablation compared

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

to surgery or other ablative strategies have reported on outcomes in patients who received cryoablation for kidney tumors. These reviews consistently found that although oncological outcomes were better with surgery, cryoablation was associated with better perioperative outcomes, lower incidence of complications, and less decline in kidney function (see Tables 2 and 3).

Case Series

In a review of strategies for treating stage 1 renal cell carcinoma, Cronan et al (2019) identified 17 articles published since 2010 describing 2,320 lesions treated with cryoablation.[10,] Mean tumor size was 2.6 cm. The overall recurrence rate was 8.1% in studies with an overall median follow-up of 41.4 months, and the technical success rate was 94.3%. Five-year OS and cancer-specific survival rates were 77.1% to 97.8% and 88% to 100%, respectively. Of the 568 lesions treated since 2016, the local recurrence rate was 3.0%. Renal function was not assessed in this review.

Recent case series have shown cryoablation associated with good oncological outcomes and preservation of renal function (Table 4).

In a single-center series reported by Morkos et al (2020), 5 of 132 patients (3.8%) transitioned to hemodialysis.[11,] The dialysis-free probability was 98% (95% CI, 0.95 to 1) at 5 years, and 95% (95% CI, 0.89 to 1) at 10 years.

In a series of 338 patients treated at 4 centers in Italy, Stacul et al (2021) reported that 93.3% of patients treated with cryoablation did not experience a significant decrease in renal function.[12,]

In another series of 170 patients with renal masses >3 cm treated between 2006 and 2016, cryoablation was associated with a lower 5-year disease-free survival compared with partial nephrectomy (75% vs 94%; p<.01).[13,] However, local recurrence was more common with cryoablation than with partial nephrectomy. There were no significant differences between modalities in 5-year metastasis-free survival or cancer-specific survival.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Table 4. Renal Function Outcomes in Longer-Term Observational Studies and Case Series of Cryoablation for Kidney Tumors

Study	Setting	N	Mean Tumor Size	Follow-up Duration	Oncological Outcomes	Renal Function Outcomes
Morkos et al (2020)[11,]	Single center	134	2.8 cm (SD+1.4 cm); range, 0.5 to 7.0 cm	10 years	Survival: 87% (95% CI, 80% to 93%) at 5 years; 72% (95% CI, 62% to 83%) at 10 years RFS: 85% (95% CI, 79% to 91%) at 5 years; 69% (95% CI, 59% to 79%) at 10 years Disease-specific survival: 94% (95% CI, 90% to 98%) at both 5 years and 10 years.	5 of 132 (3.8%) transitioned to hemodialysis Dialysis-free probability (95% CI): At 5 years: 98% (95% to 100%) At 10 years: 95% (89% to 100%)
Stacul et al (2021)[12,]	4 centers in North-Eastern Italy	338	2.53 cm	5 years	RFS: 90.5% (95% CI ,83.0% to 94.9%) at 3 years and 82.4% (95% CI, 72.0% to 89.4%) at 5 years OS: 96.0% (95% CI, 90.6% to 98.3%) at 3 years and 91.0% (95% CI, 81.7% to 95.7%) at 5 years	Cryoablation was not associated with a significant decrease in renal function after treatment in 93.3%
Pickersgill et al (2025)[13,]	N/A	170	Renal tumors > 3 cm included; mean size N/A	3.8 to 4.5 years	5-year disease-free survival: 75% with cryoablation vs 94% with partial nephrectomy Local recurrence: 5.3% with cryoablation vs 1.8% with partial nephrectomy 5-year metastases-free survival: 100% for cryoablation vs 96% for partial nephrectomy (p=.2) 5-year cancer-specific survival: 100% for cryoablation vs 98% for partial nephrectomy (p=.4)	N/A

CI: confidence interval; N/A: not available; OS: overall survival; RFS: recurrence-free survival; SD: standard deviation.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Section Summary: Individuals with Early Stage Kidney Cancer who Are Not Surgical Candidates
The evidence on cryoablation in patients with kidney cancer who are not surgical candidates consists of comparative observational studies of cryoablation compared to partial nephrectomy or other ablative techniques, systematic reviews of these studies, and case series. Although oncological outcomes were better with surgery, cryoablation was associated with less decline in kidney function. Recent case series totaling more than 500 patients showed cryoablation was associated with good oncological outcomes and preservation of renal function.

NON-SMALL CELL LUNG CANCER

Clinical Context and Therapy Purpose
The purpose of cryoablation is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with non-small cell lung cancer (NSCLC).

The following PICO was used to select literature to inform this review

Population
The relevant population of interest is individuals with NSCLC.
The review of evidence addresses the use of cryoablation in 2 populations who have NSCLC:
1. Individuals with NSCLC who are not surgical candidates;
2. Individuals with NSCLC who require palliation for a central airway obstructing lesion.

Interventions
The therapy being considered is cryoablation, also referred to as cryosurgery.

Cryoablation involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

Comparators
For medically operable NSCLC, surgery is preferred. For individuals who are medically inoperable, who refuse surgery, or who are high-risk surgical candidates, radiation therapy has a potential role, as either definitive or palliative therapy.

For individuals who require palliation for a central airway obstructing lesion, standard symptom palliative care is radiation. Chemotherapy, stent placement, and other ablative bronchoscopic therapies are also options.

Outcomes
The general outcomes of interest are OS, disease-specific survival, quality of life, and treatment-related morbidity.

The hypothesized advantages of cryosurgery for NSCLC include improved local control and benefits common to any minimally invasive procedure (eg, preserving normal organ tissue, decreasing morbidity, decreasing length of hospitalization).

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Potential complications of cryosurgery include those caused by hypothermic damage to normal tissue adjacent to the tumor, structural damage along the probe track, and secondary tumors if cancerous cells are seeded during probe removal.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

- Comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess long-term outcomes and adverse events, single-arm studies that captured longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

REVIEW OF EVIDENCE

INDIVIDUALS WITH NON-SMALL CELL LUNG CANCER WHO ARE NOT SURGICAL CANDIDATES

Systematic Reviews

Lee et al (2011) conducted a systematic review of endoscopic cryoablation of lung and bronchial tumors.[14,] Included in the review were 15 case studies and a comparative observational study. Cryoablation was performed for inoperable, advanced lung and bronchial cancers in most studies. Some studies included patients with comorbid conditions and poor general health who would not be considered surgical candidates. Complications occurred in 11.1% of patients (10 studies) and consisted of hemorrhage, mediastinal emphysema, atrial fibrillation, and dyspnea. Within 30 days of the procedure, death from hemoptysis and respiratory failure, considered to be most likely related to disease progression, occurred in 7.1% of patients.

Niu et al (2012) reviewed the literature on lung cryoablation and reported on their own experience with percutaneous cryoablation in 150 patients with NSCLC followed for 12 to 38 months.[15,] The study population had stage IIIB or IV lung cancer. Overall survival rates at 1, 2, and 3 years were 64%, 45%, and 32%, respectively. Thirty-day mortality was 2.6% and included cardiac arrest and hemopneumothorax. Complications included hemoptysis, pneumothorax, hemothorax, pleural effusion, and pulmonary infection.

Nonrandomized Studies

The Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE) assessed the safety and local recurrence-free survival after cryoablation for treatment of pulmonary metastases. Callstrom et al (2020) performed this multicenter, prospective, single-arm, phase 2 study in 128 patients with 224 lung metastases ≤3.5 cm.[16,] Median tumor size was 1.0 cm. Local recurrence-free response was 85.1% at 12 months and 77.2% at 24 months. Secondary local recurrence-free response after retreatment with cryoablation for recurrent tumors was 91.1% at 12 months and 84.4% at 24 months. Overall survival at 12 and 24 months was 97.6% and 86.6%, respectively.

The Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients-Safety and Efficacy (ECLIPSE) trial was a prospective, multicenter trial of cryoablation for metastatic disease in the lungs; interim results at 1-year follow-up were published by de Baere et al (2015).[17,] The trial

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

enrolled 40 patients with 60 metastatic lung lesions who were treated with cryoablation and had at least 12 months of follow-up. Outcomes included survival, local tumor control, quality of life, and complications. Local tumor control was achieved in 94.2% (49/52) of treated lesions, and the 1-year OS rate was 97.5% (39/40). There were no significant changes in quality of life over the 12-month study. The most common adverse event was pneumothorax requiring chest tube intubation in 18.8% (9/48 procedures). Three- and 5-year follow-up data were published by de Baere et al in 2021.[18,] Local tumor control was achieved in 87.9% (29/33) and 79.2% (19/24) per tumor at 3 and 5 years, respectively. Throughout the study duration, 5 treated patients had local progression. Overall survival at 3 and 5 years was 63.2% and 46.7%, respectively.

Moore et al (2015) reported on a prospective consecutive series of 45 patients (47 tumors) managed with cryoablation during a 5-year period (2006 to 2011).[19,] All patients had biopsy-confirmed early-stage (T1a and T1b) primary lung tumors and had been assessed by a tumor board to be medically inoperable. Lesions were as small as 5 mm, with an average of 1.9 cm (range, 0.5 to 3 cm). Cryoablation was performed under general anesthesia. The primary endpoint was the completion of the freeze-thaw cycle. Mean follow-up was 51 months, with an observed 5-year survival rate of 67.8%, 5-year cancer-specific survival rate of 56.6%, and 5-year progression-free survival rate of 87.9%. There were 7 (14.8%) local recurrences; 2 had device failure and retreatment, and another had retreatment for a tumor recurrence at 1 year after initial treatment. The ablation zone was less than 5 mm outside the margin of the tumor in 5 of the 47 treatments, and 4 of these 5 had local recurrences. Complications primarily included 19 (40%) patients with hemoptysis, 2 of which required bronchoscopy, and 24 (51%) cases of pneumothorax, 1 of which required surgical chest intubation with prolonged placement and mechanical sclerosis. These 3 (6.4%) patients were considered major complications, but there were no reports of 30-day mortality.

Section Summary: Individuals With Non-Small Cell Lung Cancer who are not Surgical Candidates

Medically inoperable patients with early stage primary lung tumors were treated with cryoablation in a consecutive series of 45 patients. Five year survival was 68%; the main complications were hemoptysis in 40% of patients and pneumothorax in 51%. A prospective single-arm Phase 2 study of 128 patients reported on cryoablation for treatment of lung metastases. Cryoablation for metastatic lung cancer was studied in a single-arm trial in 40 patients.

INDIVIDUALS WITH NON-SMALL CELL LUNG CANCER WHO REQUIRE PALLIATION FOR A CENTRAL AIRWAY OBSTRUCTING LESION

Systematic Review

Ratko et al (2013) conducted a comparative effectiveness review on local nonsurgical therapies for stage I and symptomatic obstructive NSCLC for the Agency for Healthcare Research and Quality.[20,] Cryoablation was included as a potential therapy for airway obstruction due to endoluminal NSCLC. The reviewers identified 1 RCT that randomly allocated patients to external beam radiation therapy or endobronchial treatment (clinician choice of any one endobronchial treatment: brachytherapy, laser therapy or cryotherapy). The trial was discontinued before completion due to a lack of patient accrual, and therefore, the reviewers did not include the trial in their report. Reviewers were unable to draw any conclusions about local nonsurgical therapies, including cryoablation, due to a lack of quality evidence.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Consecutive Case Series

Maiwand and Asimakopoulos (2004) reported on a consecutive series of 521 patients with symptomatic obstructive tracheobronchial malignant tumors who underwent cryosurgery with a mean of 2.4 treatments per patient.[21,] The patients were treated between 1995 and 2003, had a mean age of 67.9 years, and 72% were diagnosed with stage IIIB or IV disease. Improvement in 1 or more symptoms (hemoptysis, cough, dyspnea, chest pain) was demonstrated in 86.0% of patients. Postoperative complications were 9%, including 21 (4%) cases of hemoptysis, 12 (2%) cases of postoperative atrial fibrillation, and 16 (3%) patients developed respiratory distress and poor gas exchange that eventually resolved. There were 7 (1.2%) in-hospital deaths (the cause of death was respiratory failure in all 7 patients).

This study has several limitations, which are summarized in Tables 5 and 6.

Table 5. Study Relevance Limitations

Study	Population[a]	Intervention[b]	Comparator[c]	Outcomes[d]	Duration of Follow-up[e]
Maiwand and Asimakopoulos (2004)[21,]	3. Patients were treated 20 to 30 years ago	1. Patients were treated 20 to 30 years ago; replicable across other institutions.	2. No comparator; radiation is standard of care and other treatment options are available.	5. No description of what size improvement is important	1,2. The duration of follow-up was not described for the 521 patients (it was described for the 15 with cryosurgery at exploratory thoracotomy but those are not relevant here). The timing of the outcome measures is unclear. It is unclear if patients were evaluated on a standard schedule and at what time point improvements were seen.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

[a] Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

[b] Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4.Not the intervention of interest.

[c] Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

[d] Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

[e] Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Table 6. Study Design and Conduct Limitations

Study	Allocation[a]	Blinding[b]	Selective Reporting[c]	Data Completeness[d]	Power[e]	Statistical[f]
Maiwand and Asimakopoulos (2004)[21,]	4. No comparator, not randomized. Not clear why these patients were chosen for cryosurgery versus one of the other procedures that are available for these patients (selection bias) at this institution.	3. No blinding. All of these measures are subjective. Although these symptoms would likely not improve without treatment, the symptom reports and physician assessment of performance status are potentially biased which is complicated by the fact that there is no comparator.		1. No description of patient flow or the amount of available data for any of the outcome measures.		

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.
[a] Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.
[b] Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.
[c] Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.
[d] Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).
[e] Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.
[f] Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals a

Section Summary: Individuals with Non Small Cell Lung Cancer who Require Palliation for a Central Airway Obstructing Lesion

There are no comparative studies. A case series of 521 consecutive patients reported improvement in symptoms in 86% of patients, but multiple study design, conduct, and relevance limitations preclude drawing conclusions about the efficacy or safety of cryoablation in this population.

LOW-RISK, EARLY-STAGE BREAST CANER

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Clinical Context and Therapy Purpose

The purpose of cryoablation is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with low-risk, early-stage breast cancer.

The following PICO was used to select literature to inform this review.

Population

The relevant population of interest is individuals with low-risk, early-stage breast cancer.

Interventions

The therapy being considered is cryoablation, also referred to as cryosurgery.

Cryoablation involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

Comparators

Comparators of interest include surgical resection, other ablative techniques such as laser surgery, RFA, and argon beam coagulation.

Regarding tumors located in the breast, the selection of lumpectomy, modified radical mastectomy, or another approach is balanced against the individual's desire for breast conservation, the need for tumor-free margins in resected tissue, and the individual's age, hormone receptor status, and other factors.

Palliative treatments for bone metastases include analgesics, opioids, osteoclast inhibitors, and radiation therapy.

Outcomes

The general outcomes of interest are OS, disease-specific survival, quality of life, and treatment-related morbidity.

The hypothesized advantages of cryosurgery include improved local control and benefits common to any minimally invasive procedure (eg, preserving normal organ tissue, decreasing morbidity, decreasing length of hospitalization).

Potential complications of cryosurgery include those caused by hypothermic damage to normal tissue adjacent to the tumor, structural damage along the probe track, and secondary tumors if cancerous cells are seeded during probe removal.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- Comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess long-term outcomes and adverse events, single-arm studies that captured longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

REVIEW OF EVIDENCE

BREAST TUMORS

Systematic Reviews

Tan et al (2025) reported on a systematic review and meta-analysis evaluating local recurrence and residual tumor rates following cryoablation for small early-stage breast cancers.[22,] Studies included patients with tumors ≤ 20 mm treated with cryoablation alone or cryoablation followed by surgery. The primary outcomes were pooled local recurrence for cryoablation-only studies and pooled residual tumor rates for studies including surgical excision. Twelve studies were included, comprising 750 patients and 753 tumors; 7 studies (530 patients, 531 tumors) evaluated cryoablation alone, and 5 studies (220 patients, 222 tumors) evaluated cryoablation followed by surgery. Among cryoablation-only studies, the pooled local recurrence rate was 1.1% (95% CI, 0.42 to 3.03) with low between-study heterogeneity (I^2=0%). The largest of these studies was the prospective ICE3 study by Fine et al, described in more detail in the section below. Among studies with surgical excision, the pooled residual tumor rate was 12.0% (95% CI, 3.85 to 31.64) with substantial heterogeneity (I^2=76.1%); after exclusion of an outlier, the adjusted residual tumor rate was 8.2% (95% CI, 3.84 to 16.68) with improved heterogeneity (I^2=0%). Across included studies, tumors were predominantly invasive ductal carcinoma and hormone receptor-positive/human epidermal growth factor receptor 2-negative. Follow-up durations ranged from 1 to 104 months. Major procedure-related adverse events were not reported.

Zhao and Wu (2010) reported on a systematic review of minimally invasive ablative techniques of early-stage breast cancer.[23,] They noted that studies assessing cryoablation for breast cancer were primarily pilot and feasibility studies. Complete ablation of tumors was reported within a wide range (36% to 83%). Reviewers raised many areas of uncertainty, including patient selection criteria and the ability to precisely determine the size of tumors and achieve 100% tumor cell death. They suggested minimally invasive thermal ablation techniques for breast cancer treatment, including cryoablation, should be limited until results from prospective RCTs become available.

Prospective Nonrandomized Studies

Tables 7 and 8 describe the characteristics and results of key prospective, nonrandomized, noncomparative trials investigating cryoablation for low-risk, early-stage breast cancer.

Holmes et al (2026) reported 6-year outcomes from the FROST trial, a prospective, multicenter, nonrandomized study evaluating cryoablation as definitive local therapy for early-stage breast cancer.[24,] Eligible patients were women aged 50 years and older with unifocal, ultrasound-visible, clinical stage I (T1 ≤2.0 cm) invasive ductal carcinoma that was hormone receptor-positive and human epidermal growth factor receptor 2-negative, with clinically node-negative disease. Patients were stratified by age: those aged 70 years and older received cryoablation plus endocrine therapy alone, while those aged 50 to 69 years received cryoablation with endocrine therapy and radiotherapy, with optional sentinel lymph node biopsy. Cryoablation was performed using the Visica2 Cryoablation System. Among 83 evaluable patients, the median tumor size was 9 mm, and 82/83 (98.8%) demonstrated no residual disease on 6-month biopsy. At a median follow-up of 6.11 years, the 5-year ipsilateral breast tumor recurrence (IBTR) rate was 3.64% overall (stratum ≥70 years, 2.08%; stratum 50 to 69 years, 5.80%), with an invasive IBTR-free

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

survival rate of 97.59% (95% CI, 94.35 to 100.00). The 5-year OS rate was 96.36%, with no breast cancer-specific deaths reported. No serious treatment-related adverse events were observed.

Fine et al (2021) published interim results from the ICE3 trial, a prospective, multicenter, single-arm, nonrandomized study evaluating cryoablation without surgical excision in women aged 60 years and older with low-risk, early-stage breast cancer, defined as unifocal, ultrasound-visible invasive ductal carcinoma ≤ 1.5 cm, hormone receptor–positive, human epidermal growth factor receptor 2-negative, low to intermediate histologic grade, and clinically node-negative disease.[25,] All procedures were performed using the ProSense Cryosurgical System. The primary outcome was IBTR at 5 years. Among 194 patients who met full eligibility and received protocol-defined treatment, the mean age was 75 years, and the mean tumor dimensions were 8.1 mm (length) and 7.4 mm (width). At a mean follow-up of approximately 35 months, the overall IBTR rate was 2.06% (4/194 patients; 95% CI, 0.56 to 5.19), with a 36-month IBTR rate of 0.52% (1/194 patients; 95% CI, 0.01 to 2.84). The mean time to recurrence was 43.1 months. Adjuvant therapy was not standardized; 148 patients received endocrine therapy, 27 received radiation therapy, and 1 received chemotherapy. Device-related adverse events were reported as mild in 18.4% and moderate in 2.4%, with no severe events observed. In 2024, Fine et al published results from the 5-year follow-up of the ICE3 trial.[26,] At a mean follow-up period of approximately 54 months, the overall IBTR rate was 3.61% (7/194 patients). Based on the Kaplan-Meier estimate, the IBTR rate was 4.3% at 5 years. The mean time to recurrence was 46.72 months (range, 25.88 to 63.15 months). Most device-related adverse events were minor and resolved without residual effects. Of the 194 patients included in the study, 153 received adjuvant treatment, including 124 patients (63.9%) who received endocrine treatment only, 3 (1.5%) who underwent whole-breast radiation only, 25 (12.9%) who received endocrine plus radiation, and 1 patient (0.5%) who received endocrine, radiation, and chemotherapy.

A prospective, single-arm, phase 2 trial was published by Simmons et al (2016) for the American College of Surgeons Oncology Group Z1072.[27,] This trial enrolled 86 evaluable patients from 19 institutions with invasive ductal breast carcinoma that was 2 cm or less in size. The primary endpoint was complete ablation, defined as no residual evidence of tumor on magnetic resonance imaging. The investigators assigned a priori the success rates, indicating that cryoablation would be a potentially efficacious treatment (>90%) or that the results of cryoablation would be unsatisfactory (<70%). Following cryoablation and determination of complete ablation, all patients underwent surgery according to standard protocols for the treatment of early breast cancer. Of 87 cancers in 86 patients, complete ablation was achieved in 66 cancers (75.9%; 95% CI, 67.1% to 83.2%). Most cases without complete ablation were the result of multifocal disease outside the targeted lesion.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Table 7. Summary of Key Prospective, Nonrandomized, Noncomparative Studies

Study	Country	Dates	Participants	Treatment	Follow-Up
Holmes et al (2026)[24,]	US	July 2016 to October 2020	N=83 women aged ≥50 years; ultrasound-visible tumor; unifocal disease; clinical stage I (T1) invasive ductal carcinoma; tumor size ≤2.0 cm; HR-positive; HER2-negative; confirmed by core biopsy; no axillary adenopathy on physical examination or axillary ultrasound.	Cryoablation using the Visica2 Cryoablation System	Median, 6.11 years
Fine et al (2021)[25,]; Fine et al (2025)[26,]	US	October 2014 to February 2019	N=194 women aged ≥60 years; unifocal invasive ductal carcinoma; tumor size ≤1.5 cm; ER/PR-positive; HER2-negative; low/intermediate histologic grade (Nottingham grade 1–2); confirmed by core needle biopsy; clinically lymph node-negative on ultrasound.	Cryoablation using the ProSense Cryosurgical System	Mean, 54 months
Simmons et al (2016)[27,]	US	March 2009 to June 2013	N=86 patients with unifocal invasive ductal carcinoma ≤2 cm, with <25 % intraductal component and tumor enhancement on MRI	Cryoablation using the Visica2 Cryoablation System	NR

HER2: human epidermal growth factor receptor 2; HR: hormone receptor; MRI: magnetic resonance imaging; NR: not reported; PR: progesterone receptor

Table 8. Summary of Key Prospective, Nonrandomized, Noncomparative Study Results

Study	Successful cryoablation	3-year IBTR rate	5-year IBTR rate	IBTR-free survival rate	5-year OS	Serious AEs
Holmes et al (2026)[24,]						
Cryoablation	NR	NR	Overall, 3.64%; age ≥70 years,	Overall, 97.59%; age ≥70 years,	Overall, 96.36%; age ≥70 years,	No serious cryoablation or radiation-

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Study	Successful cryoablation	3-year IBTR rate	5-year IBTR rate	IBTR-free survival rate	5-year OS	Serious AEs
			endocrine therapy only, 2.08%; age 50 69 years, endocrine therapy plus, radiotherapy plus optional sentinel node biopsy, 5.80%	endocrine therapy only, 97.92%; age 50 69 years, endocrine therapy plus, radiotherapy plus optional sentinel node biopsy, 97.14%	endocrine therapy only, 97.92%; age 50 69 years, endocrine therapy plus, radiotherapy plus optional sentinel node biopsy, 94.20%	related AEs were observed.
Fine et al (2021)[25,]; Fine et al (2025)[26,]						
Cryoablation	NR	Overall, 0.52%	Overall, 4.3%	NR	NR	Most device-related adverse events were minor and resolved without residual effects.
Simmons et al (2016)[27,]						
Cryoablation	Overall, 75.9%	NR	NR	NR	NR	NR

AE: adverse event; IBTR: ipsilateral breast tumor recurrence; NR: not reported; OS: overall survival.

Retrospective Nonrandomized Studies

Niu et al (2013) reported on a retrospective study of 120 patients with metastatic breast cancer, including 30 metastases to the contralateral breast and other metastases to the lung, bone, liver, and skin treated with chemotherapy (n=29) or cryoablation (n=91; 35 of whom also received immunotherapy).[28,] At 10-year follow-up, the median OS of all study participants was 55 months in the cryoablation group versus 27 months in the chemotherapy group (p<.001). Moreover, the median OS was greater in patients receiving multiple cryoablation and in those receiving immunotherapy. Complications with cryotherapy to the breast included ecchymosis and hematoma, pain, tenderness, and edema; all of these complications resolved within 1 week to 1 month.

In a case series by Manteni et al (2011), who assessed 15 breast cancer patients, percutaneous cryoablation was performed 30 to 45 days before surgical resection.[29,] Resection of the lesions confirmed that complete necrosis had occurred in 14 patients, but 1 lesion had residual disease considered to be due to incorrect probe placement. In a small series of 11 patients with breast cancer tumors less than 2 cm in diameter, Pusztaszeri et al (2007) found residual tumors present

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

in 6 cases when follow-up lumpectomies were performed approximately 4 weeks after cryoablation.[30,] A case series by Sabel et al (2004) explored the role of cryoablation as an alternative to surgical excision as a primary treatment for early-stage breast cancer.[31,] This phase 1 study included 29 patients who underwent cryoablation of primary breast cancers measuring less than 2 cm in diameter, followed 1 to 4 weeks later by standard surgical excision. Cryoablation was successful in patients with invasive ductal carcinoma less than 1.5 cm in diameter, and with less than 25% ductal carcinoma in situ identified in a prior biopsy specimen.

Other studies have described outcomes from cryosurgery for advanced primary or recurrent breast cancer.[32,33,34,35,] Collectively, these reports either did not adequately describe selection criteria for trial enrollees, procedure details, or procedure-related adverse events or had inadequate study designs, analyses, and reporting of results.

Breast Fibroadenomas

A variety of case series has focused on the role of cryosurgery as an alternative to surgical excision of benign fibroadenomas. Kaufman et al (2002 to 2005) have published several case series on office-based ultrasound-guided cryoablation as a treatment of breast fibroadenomas.[36,37,38,39,40,] These case series reported on a range of 29 to 68 patients followed for 6 months to 2.6 years. It is likely that these case series included overlapping patients. At 1 year, patients reported 91% patient satisfaction and fibroadenomas became nonpalpable in 75% of cases. At follow-up averaging 2.6 years in 37 patients, the authors noted only 16% of 84% palpable fibroadenomas remained palpable after treatment and, of the fibroadenomas initially 2 cm or less in diameter, only 6% remained palpable.[40,] In this series, the authors also noted that cryoablation did not produce artifacts that could interfere with the interpretation of mammograms. These small case series, which were done by the same group of investigators, are inadequate to permit scientific conclusions.

Nurko et al (2005) reported on outcomes at 6 and 12 months for 444 treated fibroadenomas reported to the FibroAdenoma Cryoablation Treatment registry by 55 different practice settings.[41,] In these patients, before cryoablation, 75% of fibroadenomas were palpable by the patient. Follow-up at 6- and 12-month intervals showed palpable masses in 46% and 35%, respectively. When fibroadenomas were grouped by size, the treatment area was palpable in 28% of subjects for lesions 2 cm or less in diameter and 59% for lesions more than 2 cm at 12 months.

Section Summary: Breast Tumors

For the treatment of primary and recurrent breast cancer, available evidence has shown that complete ablation can be achieved in most cases for variably defined small tumors, but studies have not included control groups or compared outcomes of cryosurgery with alternative strategies for managing similar patients. Therefore, no conclusions can be made on the net health outcome of cryosurgery for breast cancer. For the treatment of fibroadenomas, there is a small body of evidence. This evidence has demonstrated that most fibroadenomas become "nonpalpable" following cryoablation. However, there is a lack of comparative trials. Comparative trials are needed to assess this technology and determine how this approach compares with surgery, as well as with vacuum-assisted excision and observation (approximately one-third of fibroadenomas regress over time after cryoablation).

SOLID TUMORS LOCATED IN THE PANCREAS OR BONE

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Clinical Context and Therapy Purpose

The purpose of cryoablation is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with solid tumors in the pancreas or bone.

The following PICO was used to select literature to inform this review.

Population

The relevant population of interest is individuals with tumors in the pancreas or bone.

Interventions

The therapy being considered is cryoablation, also referred to as cryosurgery.

Cryoablation involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

Comparators

Comparators of interest include surgical resection, other ablative techniques such as laser surgery, RFA, and argon beam coagulation.

Regarding tumors located in the breast, the selection of lumpectomy, modified radical mastectomy, or another approach is balanced against the individual's desire for breast conservation, the need for tumor-free margins in resected tissue, and the individual's age, hormone receptor status, and other factors.

Palliative treatments for bone metastases include analgesics, opioids, osteoclast inhibitors, and radiation therapy.

Outcomes

The general outcomes of interest are OS, disease-specific survival, quality of life, and treatment-related morbidity.

The hypothesized advantages of cryosurgery include improved local control and benefits common to any minimally invasive procedure (eg, preserving normal organ tissue, decreasing morbidity, decreasing length of hospitalization).

Potential complications of cryosurgery include those caused by hypothermic damage to normal tissue adjacent to the tumor, structural damage along the probe track, and secondary tumors if cancerous cells are seeded during probe removal.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- Comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess long-term outcomes and adverse events, single-arm studies that captured longer periods of follow-up and/or larger populations were sought.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

- Studies with duplicative or overlapping populations were excluded.

PANCREATIC CANCER

REVIEW OF EVIDENCE

Systematic Reviews

Tao et al (2012) reported on a systematic review of cryoablation for pancreatic cancer.[42,] Reviewers identified 29 studies and included 5. All 5 were case series and considered of low quality. Adverse events, when mentioned, included delayed gastric emptying (0% to 40.9% in 3 studies), pancreatic leak (0% to 6.8% in 4 studies), biliary leak (0% to 6.8% in 3 studies), and a single instance of upper gastrointestinal hemorrhage. Pain relief was reported in 3 studies and ranged from 66.7% to 100%. Median survival times reported in 3 studies ranged from 13.4 to 16 months. One-year total survival rates, as reported in 2 studies, were 57.5% and 63.6%. Keane et al (2014) reported on a systematic review of ablation therapy for locally advanced pancreatic cancer.[43,] Reviewers noted that studies had demonstrated ablative therapies, including cryoablation, are feasible, but larger studies are needed. No conclusions could be made on whether ablation resulted in better outcomes than best supportive care. A similar systematic review was conducted by Xue et al (2024) in patients with locally advanced pancreatic cancer with similar conclusions.[44,]

Nonrandomized Trials

Li et al (2011) reported on a retrospective study of 142 patients with unresectable pancreatic cancer treated with a palliative bypass with (n=68) or without cryoablation (n=74) from 1995 to 2002.[45,] Median dominant tumor sizes decreased from 4.3 to 2.4 cm in 36 (65%) of 55 patients 3 months after cryoablation. Survival rates did not differ significantly between groups, with the cryoablation group surviving a median of 350 days versus 257 days in the group without cryoablation. Complications did not differ significantly between groups. However, a higher percentage of delayed gastric emptying occurred in the cryoablation group (36.8%) than in the group without cryoablation (16.2%).

A pilot study assessing combination cryosurgery plus iodine 125 seed implantation for treatment of locally advanced pancreatic cancer was reported by Xu et al (2008).[46,] Forty-nine patients enrolled in the pilot study, and 12 had liver metastases; 20 patients received regional chemotherapy. At 3 months posttherapy, most patients showed tumor necrosis, with 20.4% having a complete response. Overall, the 6-, 12-, 24-, and 36-month survival rates were 94.9%, 63.1%, 22.8%, and 9.5%, respectively.

Kovach et al (2002) reported on 10 cryoablations in 9 patients with unresectable pancreatic cancer using intraoperative ultrasound guidance during laparotomy.[47,] The authors reported adequate pain control in all patients postoperatively and no intraoperative morbidity or mortality. At publication, all patients had died at an average of 5 months postoperatively (range, 1 to 11 months).

Section Summary: Pancreatic Cancer

The available evidence on cryosurgery for pancreatic cancer consists of retrospective case series that used cryosurgery for palliation of inoperable disease and a systematic review of these studies. These studies reported that pain relief was achieved in most cases and that

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

complications (eg, delayed gastric emptying) are common but the true rate of complications is uncertain. Because these studies did not include control groups or compare outcomes of cryosurgery with alternative strategies for managing similar patients, no conclusions can be made on the net health outcome of cryosurgery for pancreatic cancer.

BONE CANCER AND BONE METASTASES

Review of Evidence

Alaqeel et al (2025) published a single-arm meta-analysis to evaluate the effectiveness and safety of RFA and cryoablation for the management of painful bone metastases in adult patients.[48,] A total of 30 studies comprising 1,121 patients were included. The primary outcome was pain reduction, with secondary outcomes including tumor control and adverse events. Both RFA and cryoablation significantly reduced pain at all evaluated time points, with RFA showing the greatest effect at 6 months (standardized mean difference, -3.50; 95% CI, -4.42 to -2.27), while cryoablation demonstrated larger early effects at 24 hours (standardized mean difference, -2.43; 95% CI, -3.84 to -1.02). Indirect comparisons between cryoablation and RFA were limited by heterogeneity. Tumor control outcomes were inconsistently reported, precluding conclusions regarding comparative oncologic efficacy. Both interventions were associated with favorable safety profiles.

Meller et al (2008) retrospectively analyzed a single-center experience with 440 bone tumor cryosurgery procedures performed between 1988 and 2002, two-thirds of them for primary benign-aggressive and low-grade malignant lesions, and one-third for primary high-grade and metastatic bone tumors.[49,] At a median follow-up of 7 years (range, 3 to 18 years), the overall recurrence rate was 8%. Based on their data, the authors suggested that the ideal case for cryosurgery is a young adult with involvement of long bone, a benign-aggressive or low-grade malignant bone tumor, a good cavity with greater than 75%-thick surrounding walls, no or minimal soft-tissue component, and at least ±1 cm of subchondral bone left near a joint surface after curettage and burr drilling.

Callstrom et al (2013) reported on 61 patients treated with cryoablation for pain from 69 tumors (size, 1 to 11 cm) metastatic to the bone.[50,] Before treatment, patients rated their pain with a 4+ on a 1-to-10 scale using the Brief Pain Inventory, with a mean score of 7.1 for worst pain in a 24-hour period. The mean pain score gradually decreased after cryoablation to 1.4 ($p<.001$) at 24 weeks for worst pain in a 24-hour period. A major complication of osteomyelitis was experienced by 1 (2%) patient.

Jennings et al (2021) reported on a multicenter, single-arm prospective study of 66 patients with metastatic bone disease who were treated with cryoablation, all of whom were not candidates for or had not benefited from standard therapy.[51,] The primary endpoint was the change in pain score from baseline to week 8 and patients were followed for 24 weeks. The mean decrease in pain score from baseline to week 8 was 2.61 points (95% CI, 3.45 to 1.78). Pain scores decreased further after the primary endpoint and reached clinically meaningful levels (more than a 2-point decrease) after week 8. This study was limited by its lack of a comparator, potential for selection bias, and lack of blinding combined with subjective outcome measures.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

Section Summary: Bone Cancers and Bone Metastases
There is a small amount of literature on cryoablation for bone cancer and bone metastases. For bone metastases, the evidence base consists of a non-comparative meta-analysis and 2 single-arm nonrandomized studies (N = 61 and 66) and is inadequate to determine efficacy. Studies were limited by a lack of a comparator, potential for selection bias, and lack of blinding, combined with subjective outcome measures.

SUPPLEMENTAL INFORMATION
The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2017 Input
Clinical input was sought to help determine whether the use of cryoablation for individuals with non small cell lung cancer (NSCLC) who are either poor surgical candidates or who required palliation for a lesion obstructing the central airway would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 9 respondents, including 2 specialty society-level responses, 3 physician-level responses identified by specialty societies, and 4 physicians identified by 1 health system.

For individuals with NSCLC who are either poor surgical candidates or who required palliation for a lesion obstructing the central airway who receive cryoablation, clinical input supports this use provides a clinically meaningful improvement in net health outcome and indicates this use is consistent with generally accepted medical practice.

2009 Input
In response to requests, input was received from 2 physician specialty societies (5 reviews) and from 2 academic medical centers (3 reviews) while this policy was under review in 2009. There was strong support for the use of cryoablation in the treatment of select patients with renal tumors. There also was support for its use in the treatment of benign breast disease. Reviewers generally agreed cryoablation was investigational in the treatment of pancreatic cancer.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

American College of Radiology

The American College of Radiology Appropriateness Criteria (2009, updated 2021) for post-treatment follow-up and active surveillance of renal cell carcinoma [RCC] indicated that "Ablative therapies, such as radiofrequency ablation, microwave ablation, and cryoablation, have been shown to be effective and safe alternatives [to surgical resection] for the treatment of small, localized RCCs."[52,53,] These recommendations are based on a review of the data and expert consensus.

American Urological Association

The American Urological Association (2021) updated its guidelines on the evaluation and management of clinically localized sporadic renal masses suspicious for renal cell carcinoma.[54,] The guideline statements on thermal ablation (radiofrequency ablation, cryoablation) are listed in Table 9.

Table 9. Guidelines on Localized Masses Suspicious for Renal Cell Carcinoma

Recommendations	LOR	LOE
Guideline statement 25		
Clinicians should consider thermal ablation (TA) as an alternate approach for the management of cT1a renal masses <3 cm in size. For patients who elect TA, a percutaneous technique is preferred over a surgical approach whenever feasible to minimize morbidity.	Moderate	C
Guideline statement 26		
Both radiofrequency ablation (RFA) and cryoablation may be offered as options for patients who elect thermal ablation.	Conditional	C
Guideline statement 28		
Counseling about thermal ablation should include information regarding an increased likelihood of tumor persistence or local recurrence after primary thermal ablation relative to surgical excision, which may be addressed with repeat ablation if further intervention is elected	Strong	B

LOE: level of evidence; LOR: level of recommendation.

NATIONAL COMPREHENSIVE CANCER NETWORK

Breast Cancer

The National Comprehensive Network (NCCN) guideline on breast cancer does not include information on the use of cryoablation for breast cancer, except for ovarian ablation.[55,]

Kidney Cancer

The NCCN (v.2.2026) guideline on kidney cancer states that "percutaneous ablation (cryosurgery, radiofrequency ablation, microwave ablation) is an option for the management of clinical stage T1 renal lesions. Percutaneous ablation is suitable for renal masses ≤ 3 cm. Percutaneous ablation is an option for clinical T1b masses in select patients not eligible for surgery. Biopsy of lesions is recommended to be done prior to or at time of ablation. Percutaneous ablation may require retreatment to achieve the same local oncologic outcomes as conventional surgery. "

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

The NCCN guideline also notes that "active surveillance and percutaneous ablation such as cryotherapy, microwave ablation, or radiofrequency ablation are alternative strategies for selected patients, particularly for those who are older, those with competing health risks, and those with T1b masses not eligible for surgery." Additionally, the guidelines note that "randomized phase III comparison of percutaneous ablation with surgical resection (ie, radical or partial nephrectomy by open or laparoscopic techniques) has not been performed." [56,]

Non-Small Cell Lung Cancer

The NCCN (v.5.2026) guideline for NSCLC makes the following relevant recommendations:[57,]

- Resection is the preferred local treatment modality for medically operable disease.
- Image-guided thermal ablation (IGTA) techniques include radiofrequency ablation, microwave ablation, and cryoablation.
- IGTA may be considered for those patients who are deemed "high risk"- those with tumors that are for the most part surgically resectable but rendered medically inoperable due to comorbidities. In cases where IGTA is considered for high-risk or borderline operable patients, a multidisciplinary evaluation is recommended.
- IGTA is an option for the management of NSCLC lesions <3 cm. Ablation for NSCLC lesions >3 cm may be associated with higher rates of local recurrence and complications.
- There is evidence on the use of IGTA for selected patients with stage IA NSCLC, those who present with multiple lung cancers, or those who present with locoregional recurrence of symptomatic local thoracic disease.
- The guidelines do not separate out recommendations by ablation technique and note that "each energy modality has advantages and disadvantages. Determination of energy modality to be used for ablation should take into consideration the size and location of the target tumor, risk of complication, as well as local expertise and/or operator familiarity."

Cancer Pain

The NCCN Guideline on Adult Cancer Pain (v.1.2026) do not address cryoablation specifically for pain due to bone metastases, but note that "ablation techniques may...be helpful for pain management in patients who receive inadequate relief from pharmacological therapy."[58,]

U.S. Preventive Services Task Force Recommendations

Not applicable.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 9.

Table 9. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
Renal cancer			
NCT02399124[a]	ICESECRET PROSENSE™ Cryotherapy for Renal Cell Carcinoma Trial	120	Mar 2026 (active, not recruiting)
Breast cancer			

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT05505643	COOL-IT: Cryoablation vs Lumpectomy in T1 Breast Cancers: A Randomized Controlled Trial With Safety Lead-in	256	Apr 2033 (recruiting)
NCT07483996	Cryoablation as Alternative for Lumpectomy in Early-Stage Breast Cancer: The CRYSTAL Trial	938	Dec 2038 (not yet recruiting)
Bone cancer			
NSCLC			
NCT07272356	Investigation of the Efficacy of Local Minimally Invasive Ablative Therapy for Pulmonary Tumors and Its Impact on Respiratory Function	68	Jun 2026 (active, not recruiting)
Unpublished			
NCT04506671	A Prospective, Non-randomized, in Parallel Groups Study Evaluating the Efficacy and Safety of Percutaneous Cryoablation and Partial Nephrectomy in Localized T1b Renal Tumor	142	Jun 2025 (unknown)
NCT04334785	Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer	186	May 2025 (unknown)
NCT05615545	Safety and Efficacy of Cryoablation in the Treatment of Advanced Bone and Soft Tissue Tumors: a Single-center Retrospective Study	30	Oct 2024 (unknown)

NCT: national clinical trial.
[a] Denotes industry-sponsored or cosponsored trial.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

CODING

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.

Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.

CPT/HCPCS	
19105	Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma
20983	Ablation therapy for reduction or eradication of 1 or more bone tumors (e.g., metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; cryoablation
32994	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation
50250	Ablation, open, 1 or more renal mass lesion(s), cryosurgical, including intraoperative ultrasound guidance and monitoring, if performed
50542	Laparoscopy, surgical; ablation of renal mass lesion(s), including intraoperative ultrasound guidance and monitoring, when performed
50593	Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy
0581T	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral

REVISIONS	
03-04-2019	Policy added to the bcbsks.com web site on 02-01-2019 with an effective date of 03-04-2019.
01-01-2020	In Coding section: ▪ Added CPT Code: 0581T
04-19-2021	Updated Description section
	Updated Rationale
	Updated References
09-17-2021	Changed Title from "Cryosurgical Ablation of Miscellaneous Solid Tumors Other Than Liver, Prostate, or Dermatologic Tumors" to "Cryoablation of Tumors Located in the Kidney, Lung, Breast, Pancreas, or Bone"
	Updated Rationale
	Updated References
08-23-2022	Updated Description Section
	Updated Rationale Section
	Updated Coding Section ▪ Removed ICD-10 Codes: C64.1, C64.2, C64.9, C65.1, C65.2

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

REVISIONS	
	▪ Added: "An appropriate ICD-10 diagnosis should be used when reporting Cryoablation of Tumors Located in the Kidney, Lung, Breast, Pancreas, or Bone.:" statement to the ICD-10 section
	Updated References Section
09-12-2023	Updated Description Section
	Updated Rationale Section
	Updated Coding Section ▪ Removed ICD-10 Diagnoses Box
	Updated References Section
08-27-2024	Updated Description Section
	Updated Rationale Section
	Updated References Section
08-26-2025	Updated Description Section
	Updated Rationale Section
	Updated References Section
09-08-2026	Updated Description Section
	Updated Policy Section ▪ Removed from Statement C: lung (other than defined above), pancreas, or bone and other solid tumors or metastases outside the liver and prostate and to treat renal cell carcinomas in individuals who are surgical candidates. ▪ Added Statement D: Cryosurgical ablation is considered experimental / investigational as a treatment for lung (other than defined above), pancreas, or bone, and to treat renal cell carcinomas in individuals who are surgical candidates.
	Updated Rationale Section
	Updated References Section

REFERENCES

1. Gao H, Zhou L, Zhang J, et al. Comparative efficacy of cryoablation versus robot-assisted partial nephrectomy in the treatment of cT1 renal tumors: a systematic review and meta-analysis. BMC Cancer. Sep 16 2024; 24(1): 1150. PMID 39285347
2. Yanagisawa T, Mori K, Kawada T, et al. Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. Urol Oncol. Jul 2022; 40(7): 315-330. PMID 35562311
3. Uhlig J, Strauss A, Rücker G, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. Eur Radiol. Mar 2019; 29(3): 1293-1307. PMID 30255245
4. Klatte T, Shariat SF, Remzi M. Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. J Urol. May 2014; 191(5): 1209-17. PMID 24231845
5. Tang K, Yao W, Li H, et al. Laparoscopic renal cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal masses: a systematic review and meta-analysis of comparative studies. J Laparoendosc Adv Surg Tech A. Jun 2014; 24(6): 403-10. PMID 24914926
6. Andrews JR, Atwell T, Schmit G, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol. Aug 2019; 76(2): 244-251. PMID 31060824

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

7. Rembeyo G, Correas JM, Jantzen R, et al. Percutaneous Ablation Versus Robotic Partial Nephrectomy in the Treatment of cT1b Renal Tumors: Oncologic and Functional Outcomes of a Propensity Score-weighted Analysis. Clin Genitourin Cancer. Apr 2020; 18(2): 138-147. PMID 31982346
8. Yan S, Yang W, Zhu CM, et al. Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2cm or sized 2-4cm: A population-based study. Medicine (Baltimore). May 2019; 98(21): e15610. PMID 31124938
9. Pecoraro A, Palumbo C, Knipper S, et al. Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer. J Urol. Dec 2019; 202(6): 1120-1126. PMID 31347950
10. Cronan J, Dariushnia S, Bercu Z, et al. Systematic Review of Contemporary Evidence for the Management of T1 Renal Cell Carcinoma: What IRs Need to Know for Kidney Cancer Tumor Boards. Semin Intervent Radiol. Aug 2019; 36(3): 194-202. PMID 31435127
11. Morkos J, Porosnicu Rodriguez KA, Zhou A, et al. Percutaneous Cryoablation for Stage 1 Renal Cell Carcinoma: Outcomes from a 10-year Prospective Study and Comparison with Matched Cohorts from the National Cancer Database. Radiology. Aug 2020; 296(2): 452-459. PMID 32515677
12. Stacul F, Sachs C, Giudici F, et al. Cryoablation of renal tumors: long-term follow-up from a multicenter experience. Abdom Radiol (NY). Sep 2021; 46(9): 4476-4488. PMID 33912986
13. Pickersgill NA, Vetter JM, Mittauer DJ, et al. Intermediate-Term Oncologic Outcomes of Partial Nephrectomy vs Cryoablation in Renal Tumors 3 cm: A Propensity Score-Matched Analysis. J Urol. Jul 2025; 214(1): 32-40. PMID 40073100
14. Lee SH, Choi WJ, Sung SW, et al. Endoscopic cryotherapy of lung and bronchial tumors: a systematic review. Korean J Intern Med. Jun 2011; 26(2): 137-44. PMID 21716589
15. Niu L, Xu K, Mu F. Cryosurgery for lung cancer. J Thorac Dis. Aug 2012; 4(4): 408-19. PMID 22934144
16. Callstrom MR, Woodrum DA, Nichols FC, et al. Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE). J Thorac Oncol. Jul 2020; 15(7): 1200-1209. PMID 32151777
17. de Baere T, Tselikas L, Woodrum D, et al. Evaluating Cryoablation of Metastatic Lung Tumors in Patients--Safety and Efficacy: The ECLIPSE Trial--Interim Analysis at 1 Year. J Thorac Oncol. Oct 2015; 10(10): 1468-74. PMID 26230972
18. de Baère T, Woodrum D, Tselikas L, et al. The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up. J Thorac Oncol. Nov 2021; 16(11): 1840-1849. PMID 34384914
19. Moore W, Talati R, Bhattacharji P, et al. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol. Mar 2015; 26(3): 312-9. PMID 25735518
20. Ratko TA, Vats V, Brock J, et al. Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non- Small-Cell Lung Cancer (AHRQ Comparative Effectiveness Review No. 112). Rockville, MD: Agency for Healthcare Research and Quality; 2013.
21. Maiwand MO, Asimakopoulos G. Cryosurgery for lung cancer: clinical results and technical aspects. Technol Cancer Res Treat. Apr 2004; 3(2): 143-50. PMID 15059020
22. Tan E, Chong J, Pua U, et al. Local recurrence and residual tumor rates following cryoablation for small early-stage breast cancers: systemic review and meta-analysis. Breast Cancer. Jan 2025; 32(1): 69-78. PMID 39425821

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

23. Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. Eur J Surg Oncol. Dec 2010; 36(12): 1149-55. PMID 20889281
24. Holmes DR, Manoian S, Rahman RL, et al. Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial. Ann Surg Oncol. Apr 2026; 33(4): 3374-3382. PMID 41538117
25. Fine RE, Gilmore RC, Dietz JR, et al. Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial. Ann Surg Oncol. Oct 2021; 28(10): 5525-5534. PMID 34392462
26. Fine RE, Gilmore RC, Tomkovich KR, et al. Cryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence. Ann Surg Oncol. Oct 2024; 31(11): 7273-7283. PMID 39283572
27. Simmons RM, Ballman KV, Cox C, et al. A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. Ann Surg Oncol. Aug 2016; 23(8): 2438-45. PMID 27221361
28. Niu L, Mu F, Zhang C, et al. Cryotherapy protocols for metastatic breast cancer after failure of radical surgery. Cryobiology. Aug 2013; 67(1): 17-22. PMID 23619024
29. Manenti G, Perretta T, Gaspari E, et al. Percutaneous local ablation of unifocal subclinical breast cancer: clinical experience and preliminary results of cryotherapy. Eur Radiol. Nov 2011; 21(11): 2344-53. PMID 21681574
30. Pusztaszeri M, Vlastos G, Kinkel K, et al. Histopathological study of breast cancer and normal breast tissue after magnetic resonance-guided cryotherapy ablation. Cryobiology. Aug 2007; 55(1): 44-51. PMID 17604016
31. Sabel MS, Kaufman CS, Whitworth P, et al. Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. Ann Surg Oncol. May 2004; 11(5): 542-9. PMID 15123465
32. Tanaka S. Cryosurgical treatment of advanced breast cancer. Skin Cancer. Jan 1995;10:9-18.
33. Pfleiderer SO, Freesmeyer MG, Marx C, et al. Cryotherapy of breast cancer under ultrasound guidance: initial results and limitations. Eur Radiol. Dec 2002; 12(12): 3009-14. PMID 12439583
34. Suzuki Y. Cryosurgical treatment of advanced breast cancer and cryoimmunological responses. Skin Cancer. 1995;10:19-26.
35. Morin J, Traoré A, Dionne G, et al. Magnetic resonance-guided percutaneous cryosurgery of breast carcinoma: technique and early clinical results. Can J Surg. Oct 2004; 47(5): 347-51. PMID 15540687
36. Kaufman CS, Bachman B, Littrup PJ, et al. Office-based ultrasound-guided cryoablation of breast fibroadenomas. Am J Surg. Nov 2002; 184(5): 394-400. PMID 12433600
37. Kaufman CS, Littrup PJ, Freman-Gibb LA, et al. Office-based cryoablation of breast fibroadenomas: 12-month followup. J Am Coll Surg. Jun 2004; 198(6): 914-23. PMID 15194073
38. Kaufman CS, Bachman B, Littrup PJ, et al. Cryoablation treatment of benign breast lesions with 12-month follow-up. Am J Surg. Oct 2004; 188(4): 340-8. PMID 15474424
39. Littrup PJ, Freeman-Gibb L, Andea A, et al. Cryotherapy for breast fibroadenomas. Radiology. Jan 2005; 234(1): 63-72. PMID 15550369
40. Kaufman CS, Littrup PJ, Freeman-Gibb LA, et al. Office-based cryoablation of breast fibroadenomas with long-term follow-up. Breast J. 2005; 11(5): 344-50. PMID 16174156

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

41. Nurko J, Mabry CD, Whitworth P, et al. Interim results from the FibroAdenoma Cryoablation Treatment Registry. Am J Surg. Oct 2005; 190(4): 647-51; discussion 651-2. PMID 16164941
42. Tao Z, Tang Y, Li B, et al. Safety and effectiveness of cryosurgery on advanced pancreatic cancer: a systematic review. Pancreas. Jul 2012; 41(5): 809-11. PMID 22695092
43. Keane MG, Bramis K, Pereira SP, et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol. Mar 07 2014; 20(9): 2267-78. PMID 24605026
44. Xue K, Liu X, Xu X, et al. Perioperative outcomes and long-term survival of cryosurgery on unresectable pancreatic cancer: a systematic review and meta-analysis. Int J Surg. Jul 01 2024; 110(7): 4356-4369. PMID 38537056
45. Li J, Chen X, Yang H, et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Postgrad Med J. Feb 2011; 87(1024): 89-95. PMID 21131612
46. Xu KC, Niu LZ, Hu YZ, et al. A pilot study on combination of cryosurgery and (125)iodine seed implantation for treatment of locally advanced pancreatic cancer. World J Gastroenterol. Mar 14 2008; 14(10): 1603-11. PMID 18330956
47. Kovach SJ, Hendrickson RJ, Cappadona CR, et al. Cryoablation of unresectable pancreatic cancer. Surgery. Apr 2002; 131(4): 463-4. PMID 11935137
48. Alaqeel M, Alnajres A, Mulia Y, et al. Radiofrequency Ablation and Cryoablation in Treating Painful Bone Metastasis: A Comprehensive Systematic Review and Separate Single-Arm Meta-analysis. Orthop Rev (Pavia). 2025; 17: 150315. PMID 41450487
49. Meller I, Weinbroum A, Bickels J, et al. Fifteen years of bone tumor cryosurgery: a single-center experience of 440 procedures and long-term follow-up. Eur J Surg Oncol. Aug 2008; 34(8): 921-927. PMID 18158228
50. Callstrom MR, Dupuy DE, Solomon SB, et al. Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. Cancer. Mar 01 2013; 119(5): 1033-41. PMID 23065947
51. Jennings JW, Prologo JD, Garnon J, et al. Cryoablation for Palliation of Painful Bone Metastases: The MOTION Multicenter Study. Radiol Imaging Cancer. Mar 2021; 3(2): e200101. PMID 33817650
52. Purysko AS, Nikolaidis P, Khatri G, et al. ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Carcinoma: 2021 Update. J Am Coll Radiol. May 2022; 19(5S): S156-S174. PMID 35550799
53. American College of Radiology (ACR). ACR Appropriateness Criteria: Post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma. Updated 2021. https://acsearch.acr.org/docs/69365/Narrative/ Accessed May 19, 2026.
54. Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. Aug 2021; 206(2): 199-208. PMID 34115547
55. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2026. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed May 20, 2026.
56. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2.2026. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed May 14, 2026.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

57. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 5.2026. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed May 15, 2026.
58. National Comprehensive Cancer Network. Adult Cancer Pain. Version 1.2026. https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed May 16, 2026

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information